This firm has accumulated 9.34
M in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the firm is not taking enough advantage from borrowing.
The company holds a Beta of -0.027, which implies not very significant fluctuations relative to the market. Let's try to break down what Oxford's beta means in this case. As returns on the market increase, returns on owning Oxford Biomedical are expected to decrease at a much lower rate. During the bear market, Oxford Biomedical is likely to outperform the market. Even though it is essential to pay attention to
Oxford Biomedical current trending patterns, it is always good to be careful when utilizing equity existing
price patterns. Our philosophy towards forecasting any stock's
future performance is to check both, its past performance charts as well as the business as a whole, including all available
technical indicators. Oxford Biomedical exposes twenty-eight different technical indicators, which can help you to evaluate its performance.
Oxford Biomedical has an expected return of -0.7%. Please be advised to check Oxford Biomedical
information ratio,
value at risk,
kurtosis, as well as the
relationship between the
sortino ratio and
semi variance to decide if
Oxford Biomedical performance from the past will be repeated at some point in the near future.
Oxford Biomedica financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Oxford Biomedica, including all of Oxford Biomedica's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Oxford Biomedica assets, the company is considered highly leveraged. Understanding the
composition and structure of overall Oxford Biomedica debt and outstanding corporate bonds gives a good idea of
how risky the capital structure of a business is and if it is worth investing in it. Please read more on our
technical analysis page.
How important is Oxford Biomedica's Liquidity
Oxford Biomedica
financial leverage refers to using borrowed capital as a funding source to finance Oxford Biomedica plc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Oxford Biomedica financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Oxford Biomedica's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Oxford Biomedica's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Oxford Biomedica's total debt and its cash.
Is Oxford Biomedica valued objectively by the market?
The company reported the revenue of 142.8
M. Net Income was 19.01
M with profit before overhead, payroll, taxes, and interest of 82.64
M.
Will Oxford Biomedical latest dip continue?
Latest jensen alpha is at -0.66. Oxford Biomedical exhibits very low volatility with skewness of -2.4 and kurtosis of 8.29. However, we advise investors to further study Oxford Biomedical technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Oxford Biomedical's otc stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Oxford Biomedical's otc stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Oxford Biomedical Implied Volatility
Oxford Biomedical's implied volatility exposes the market's sentiment of Oxford Biomedical stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Oxford Biomedical's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Oxford Biomedical stock will not fluctuate a lot when Oxford Biomedical's options are near their expiration.
Our Conclusion on Oxford Biomedical
Although many other companies in the biotechnology industry are either recovering or due for a correction, Oxford Biomedical may not be performing as strong as the other in terms of long-term growth potentials. Taking everything into account, as of the 5th of July 2022, our analysis shows that Oxford Biomedical moves indifferently to market moves. The firm is
undervalued and projects
very low probability of financial unrest for the next 2 years. Our primary 90 days 'Buy-Sell' recommendation on the firm is
Strong Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Oxford Biomedica plc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com